132 related articles for article (PubMed ID: 35964532)
21. Treatment of a cerebral pial arteriovenous fistula in a patient with sickle cell disease-related moyamoya syndrome: case report.
Lo Presti A; Weil AG; Fallah A; Peterson EC; Niazi TN; Bhatia S
J Neurosurg Pediatr; 2015 Aug; 16(2):207-11. PubMed ID: 26053963
[TBL] [Abstract][Full Text] [Related]
22. The excess burden of stroke in hospitalized adults with sickle cell disease.
Strouse JJ; Jordan LC; Lanzkron S; Casella JF
Am J Hematol; 2009 Sep; 84(9):548-52. PubMed ID: 19623672
[TBL] [Abstract][Full Text] [Related]
23. First Ischemic Stroke in Sickle-Cell Disease: Are There Any Adult Specificities?
Calvet D; Bernaudin F; Gueguen A; Hosseini H; Habibi A; Galactéros F; Bartolucci P
Stroke; 2015 Aug; 46(8):2315-7. PubMed ID: 26173728
[TBL] [Abstract][Full Text] [Related]
24. Clinical Presentation and Stroke Incidence Differ by Moyamoya Etiology.
Gatti JR; Torriente AG; Sun LR
J Child Neurol; 2021 Mar; 36(4):272-280. PubMed ID: 33155871
[TBL] [Abstract][Full Text] [Related]
25. Sickle cell disease and coronavirus disease-2019 (COVID-19) infection: a single-center experience.
Devarashetty SP; Grewal US; Le Blanc K; Walton J; Jones T; Shi R; Master SR; Mansour RP; Ramadas P
Postgrad Med J; 2023 Aug; 99(1175):1008-1012. PubMed ID: 37399057
[TBL] [Abstract][Full Text] [Related]
26. Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States.
Kourtis AP; Bansil P; Johnson C; Meikle SF; Posner SF; Jamieson DJ
Pediatr Infect Dis J; 2007 May; 26(5):406-10. PubMed ID: 17468650
[TBL] [Abstract][Full Text] [Related]
27. The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia.
Amlie-Lefond C; Flanagan J; Kanter J; Dobyns WB
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):2897-2904. PubMed ID: 30076115
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1.
Brosius SN; Vossough A; Fisher MJ; Lang SS; Beslow LA; George BJ; Ichord R
Pediatr Neurol; 2022 Sep; 134():85-92. PubMed ID: 35849956
[TBL] [Abstract][Full Text] [Related]
29. Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience.
Winstead M; Sun PP; Martin K; Earl J; Neumayr L; Hoppe C; Vichinsky E
Pediatr Hematol Oncol; 2017 Mar; 34(2):100-106. PubMed ID: 28532265
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of COVID-19 hospitalizations in patients with sickle cell disease: A nationwide analysis.
Ilerhunmwuwa NP; Inyang L; Hakobyan N; Wasifuddin M; Tahir M; Aiwuyo H; Ankah P; Torere BE; Amaechi UM; Wang JC
Eur J Haematol; 2023 Sep; 111(3):432-440. PubMed ID: 37290934
[TBL] [Abstract][Full Text] [Related]
31. High Prevalence of Moyamoya Syndrome in Appalachia.
Nisiewicz MJ; Roberts JM; Dobbs MR; Ajadi EA; Kitzman P; Wolfe M; Elkins K; Dugan AJ; Fraser JF
Cerebrovasc Dis; 2020; 49(5):516-521. PubMed ID: 33027801
[TBL] [Abstract][Full Text] [Related]
32. Trends in hospitalizations and epidemiological characteristics of adults Moyamoya disorder in the United States.
Patel SD; Desai N; Rane S; Patel N; Desai R; Mehta T; Ollenschleger MD; Nanda A; Starke RM; Khandelwal P
J Neurol Sci; 2020 Dec; 419():117165. PubMed ID: 33059298
[TBL] [Abstract][Full Text] [Related]
33. Encephaloduroateriosynangiosis (EDAS) in the management of Moyamoya syndrome in children with sickle cell disease.
Alamri A; Hever P; Cheserem J; Gradil C; Bassi S; Tolias CM
Br J Neurosurg; 2019 Apr; 33(2):161-164. PubMed ID: 28616936
[TBL] [Abstract][Full Text] [Related]
34. Preoperative clinical symptomatology and stroke burden in pediatric moyamoya angiopathy: Defining associated risk variables.
Hackenberg A; Battilana B; Hebeisen M; Steinfeld R; Khan N
Eur J Paediatr Neurol; 2021 Nov; 35():130-136. PubMed ID: 34715507
[TBL] [Abstract][Full Text] [Related]
35. The burden of obstructive sleep apnea in pediatric sickle cell disease: a Kids' inpatient database study.
Tsou PY; Cielo CM; Xanthopoulos MS; Wang YH; Kuo PL; Tapia IE
Sleep; 2021 Feb; 44(2):. PubMed ID: 32835382
[TBL] [Abstract][Full Text] [Related]
36. Declining stroke rates in Californian children with sickle cell disease.
Fullerton HJ; Adams RJ; Zhao S; Johnston SC
Blood; 2004 Jul; 104(2):336-9. PubMed ID: 15054044
[TBL] [Abstract][Full Text] [Related]
37. Stroke and presence of patent foramen ovale in sickle cell disease.
Aggeli C; Polytarchou K; Dimitroglou Y; Patsourakos D; Delicou S; Vassilopoulou S; Tsiamis E; Tsioufis K
J Thromb Thrombolysis; 2021 Oct; 52(3):889-897. PubMed ID: 33638018
[TBL] [Abstract][Full Text] [Related]
38. Mortality and Hospitalizations among Sickle Cell Disease Patients with End-Stage Kidney Disease Initiating Dialysis.
Olaniran KO; Eneanya ND; Zhao SH; Ofsthun NJ; Maddux FW; Thadhani RI; Dalrymple LS; Nigwekar SU
Am J Nephrol; 2020; 51(12):995-1003. PubMed ID: 33486484
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in Patients with Moyamoya Syndrome and Sickle Cell Disease: A Systematic Review.
Newman S; Boulter JH; Malcolm JG; Pradilla I; Pradilla G
World Neurosurg; 2020 Mar; 135():165-170. PubMed ID: 31790841
[TBL] [Abstract][Full Text] [Related]
40. Ischemic sequelae and other vascular diseases.
Kaseka ML; Dlamini N; Westmacott R
Handb Clin Neurol; 2020; 173():485-492. PubMed ID: 32958192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
